Skip to Content
Search Menu

Doctors and patients struggle to stay up-to-date with immunotherapy

Research projects presented at ESMO 2021 reveal that non-oncology doctors and patients have limited understanding of immunotherapy.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

Marco Donia

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

/ Marco Donia
ESMO24ImmunotherapyMelanoma Play the Video 4:39
Andrea Botticelli

Efficacy and Safety of Targeted Therapy vs Standard of Care in Patients with Solid Tumors

/ Andrea Botticelli
ESMO24Immunotherapy Play the Video 05:07

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunotherapyLung cancerNSCLCWCLC23

LAG3 Inhibitors Change The Landscape Of Immunotherapy

/ Marco Donia / Eva Ellebæk
ImmunotherapyMelanoma
Loulieta Nazerai

Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade

/ Loulieta Nazerai
CancerImmunotherapy Play the Video 9:49
Jon Amund Kyte

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Jon Amund Kyte
Breast cancerESMO22Immunotherapy Play the Video 7:23

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynecological cancer Play the Video 9:01

FDG-PET-CT scans as a decision tool for early immunotherapy discontinuation in advanced melanoma

/ Eva Ellebæk
ImmunotherapyMelanoma Play the Video 6:48
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynecological cancer Play the Video 9:01
Back to top